Investigators sought to determine whether adding gedatolisib to fulvestrant, with or without palbociclib, improved clinical outcomes in patients with HR-positive/HER2-negative/PIK3CA wild-type ...

A treatment regimen of penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) achieved its primary endpoint in newly diagnosed primary central nervous system lymphoma ...

Clinically meaningful activity was observed in 57 patients at 400 mg BID fed, including 11.1-month median PFS and mutation-subtype–agnostic benefit across kinase versus nonkinase PIK3CA variants.

The MarketWatch News Department was not involved in the creation of this content. Multiple long-term follow-up studies confirm BRUKINSA's superior efficacy and favorable tolerability versus ibrutinib ...

Please provide your email address to receive an email when new articles are posted on . Women with advanced ovarian cancer derived significant quality-adjusted PFS benefit from niraparib compared with ...

In younger patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFRC) led to strong progression-free survival (PFS) and durable ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

Proton beam therapy induced survival outcomes that were equal to or better than photon radiotherapy, and may represent a viable treatment option for some patients with pediatric neuroblastoma.

Toripalimab plus chemotherapy significantly improved progression-free survival and overall survival over chemotherapy alone in patients with advanced NSCLC while having a manageable safety profile.

Multiple long-term follow-up studies confirm BRUKINSA’s superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLL Additional ASH data from investigational BTK ...